rofecoxib has been researched along with Obesity in 4 studies
Obesity: A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).
| Excerpt | Relevance | Reference |
|---|---|---|
| "The potential prothrombotic effect of the cyclooxygenase-2 (COX-2) inhibitor Rofecoxib (Vioxx) was investigated using murine thrombosis models." | 7.74 | Prothrombotic effect of Rofecoxib in a murine venous thrombosis model. ( Gallacher, DJ; Hoylaerts, MF; Lijnen, HR; Lu, HR; Nagai, N, 2008) |
| "The effect of rofecoxib (Vioxx), a cyclooxygenase (COX)-2 inhibitor, on adipose tissue development was studied in a murine model of diet-induced obesity." | 7.74 | Rofecoxib impairs adipose tissue development in a murine model of nutritionally induced obesity. ( Gallacher, DJ; Lijnen, HR; Lu, HR; Van Hoef, B, 2008) |
| "The potential prothrombotic effect of the cyclooxygenase-2 (COX-2) inhibitor Rofecoxib (Vioxx) was investigated using murine thrombosis models." | 3.74 | Prothrombotic effect of Rofecoxib in a murine venous thrombosis model. ( Gallacher, DJ; Hoylaerts, MF; Lijnen, HR; Lu, HR; Nagai, N, 2008) |
| "The effect of rofecoxib (Vioxx), a cyclooxygenase (COX)-2 inhibitor, on adipose tissue development was studied in a murine model of diet-induced obesity." | 3.74 | Rofecoxib impairs adipose tissue development in a murine model of nutritionally induced obesity. ( Gallacher, DJ; Lijnen, HR; Lu, HR; Van Hoef, B, 2008) |
| "Rofecoxib treatment decreased urinary PGF2alpha and 8-isoprostane levels in obese Zucker rats." | 1.32 | Rofecoxib decreases renal injury in obese Zucker rats. ( Dey, A; Imig, JD; Kaesemeyer, WH; Maric, C; Pollock, JS; Stewart, J; Zaharis, CZ, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Nagai, N | 1 |
| Hoylaerts, MF | 1 |
| Gallacher, DJ | 2 |
| Lu, HR | 2 |
| Lijnen, HR | 3 |
| Van Hoef, B | 1 |
| Dey, A | 1 |
| Maric, C | 1 |
| Kaesemeyer, WH | 1 |
| Zaharis, CZ | 1 |
| Stewart, J | 1 |
| Pollock, JS | 1 |
| Imig, JD | 1 |
4 other studies available for rofecoxib and Obesity
| Article | Year |
|---|---|
Prothrombotic effect of Rofecoxib in a murine venous thrombosis model.
Topics: Animals; Cyclooxygenase 2 Inhibitors; Disease Models, Animal; Femoral Artery; Jugular Veins; Lactone | 2008 |
Rofecoxib impairs adipose tissue development in a murine model of nutritionally induced obesity.
Topics: Adipose Tissue; Animals; Blood Glucose; Cyclooxygenase 2 Inhibitors; Dietary Fats; Disease Models, A | 2008 |
Effect of Vioxx on adipose tissue development in mice with genetically determined obesity.
Topics: Adipose Tissue; Animals; Anti-Obesity Agents; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Disease | 2008 |
Rofecoxib decreases renal injury in obese Zucker rats.
Topics: Animals; Chemokines; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Cytoc | 2004 |